ESC Guidance for ACS Flashcards

1
Q

What high-risk features would suggest against a delayed invasive strategy in NSTEMI?

A
  • Hemodynamic instability
  • Severe heart failure
  • Ventricular arrhythmias
  • Ongoing ischaemic pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What risk factors, if present in a NSTEMI diagnosis, would prompt an early invasive strategy?

A
  • Hemodynamic instability
  • Severe left ventricular dysfunction
  • High-risk score (e.g., GRACE)
  • Recurrent or persistent angina despite medical therapy
  • Significant ST-segment depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does the GRACE score predict in patients with NSTEMI/UA?

A

Risk of adverse cardiovascular events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Name cardiovascular risk factors that are optimised in secondary prevention

A
  • Hypertension
  • Diabetes
  • Hyperlipidaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the purpose of optimising cardiovascular risk factors in secondary prevention?

A

To reduce complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the components of secondary prevention after ACS?

A

Lifestyle modifications
Pharmacotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the primary focus of secondary prevention after ACS?

A

Reduce complications and risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the default DAPT duration for ACS patients? When might shorter DAPT durations be considered?

A

12 hours
In high bleeding risk patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What therapy typically follows DAPT after 12 months?

A

Lifelong aspirin monotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which P2Y12 inhibitors might be considered for patients with high bleeding risk (HBR)?

A

Ticagrelor or clopidogrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Why is aspirin + prasugrel the preferred DAPT for patients undergoing or following PCI?

A

Greater potency, faster onset, reduced thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the preferred DAPT for patients undergoing or following PCI?

A

Aspirin + prasugrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Is pre-treatment with P2Y12 inhibitors recommended in ACS?

A

No, evidence does not support early efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why is unfractionated heparin (UFH) typically first-line for ACS?

A

Rapid onset, reversibility, proven efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which antithrombotic agent is typically first-line for ACS?

A

Unfractionated heparin (UFH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

According to the ESC guide, what is ACS caused by?

A

Acute myocardial ischaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the underlying issue in acute myocardial ischemia?

A

Reduced blood flow in the coronary arteries

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What conditions are included within the spectrum of ACS?

A
  • Unstable angina (UA)
  • Non-ST-elevation myocardial infarction (NSTEMI)
  • ST-elevation myocardial infarction (STEMI)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

In the context of ACS, what does a “stable patient” refer to?

A

Patients without cardiogenic shock

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the consequence of cardiogenic shock?

A

Reduced perfusion to bodily tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are some complications associated with ACS?

A

Heart failure (HF)
Severe arrhythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are the key components of the diagnostic process for ACS conditions?

A

Clinical presentation
ECG
Biomarkers
Risk stratification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What ECG finding is characteristic of STEMI? What ECG findings are associated with NSTEMI/UA?

A

ST-segment elevation
ST depression, T-wave changes

24
Q

What does a rise and fall in troponin levels indicate?

A

Myocardial necrosis

25
Q

According to ACS pathways, what characterizes STEMI?

A
  • ST elevation
  • Total occlusion
  • Requires immediate reperfusion (PCI or fibrinolysis)
26
Q

What ECG findings might be observed in NSTEMI patients? In NSTEMI, what accompanies the ECG findings?

A

Transient ST elevation, ST depression, T-wave abnormalities
Rise and fall in troponin

27
Q

How is unstable angina diagnosed in relation to troponin levels?

A

Troponin levels remain below the 99th percentile

28
Q

Why does STEMI require immediate reperfusion?

A

Medical emergency

29
Q

What is the preferred reperfusion strategy for STEMI if performed promptly?

A

Primary PCI

30
Q

How soon should primary PCI be performed from first medical contact for STEMI? If PCI is unavailable, how soon should fibrinolysis be administered after hospital arrival for STEMI?

A

Within 120 minutes
Within 10 minutes

31
Q

After fibrinolysis, how is ECG monitored to assess effectiveness in STEMI?

A

60-90 minutes after IV bolus

32
Q

What reduction in ST-segment elevation after fibrinolysis indicates the need for PCI?

33
Q

Why is time delay critical in STEMI management?

A

It contributes to mortality and poor outcomes

34
Q

How does NSTEMI management differ from STEMI management regarding time restrictions?

A

NSTEMI has less time restrictions

35
Q

What characterises NSTEMI with a very high risk of complications?

A

Immediate invasive strategy

36
Q

How soon is routine invasive angiography performed in an early invasive strategy for NSTEMI?

A

Within 24 hours

37
Q

How soon is invasive angiography typically performed in a delayed invasive strategy?

A

Within 48 hours

38
Q

For which patients is a delayed invasive strategy typically used?

A

Low-risk patients without high-risk features

39
Q

What is the initial event in acute coronary syndromes (ACS)?

A

Plaque rupture or plaque erosion

40
Q

What happens during plaque rupture or erosion?

A

Underlying thrombogenic material is exposed

41
Q

How do activated platelets bind to each other?
What is formed when activated platelets bind to each other?

A

Via glycoprotein IIb/IIIa receptors
A platelet-rich clot

42
Q

What is the role of fibrin in clot formation?

A

Stabilises the clot

43
Q

What type of therapy should all patients with ACS be started on upon hospital admission?

A

Antithrombotic therapy

44
Q

Why is unfractionated heparin (UFH) typically first-line for ACS?

A

Rapid onset, reversibility, proven efficacy

45
Q

Which factor mediates the linking of platelets to collagen?

A

Von Willebrand Factor

46
Q

Which molecules exposed at the site of vessel injury recruit platelets? What change in platelet shape indicates its activation?

A

Collagen and von Willebrand Factor
Change into dendritic form

47
Q

What prothrombotic molecule is released by activated platelets?

A

Adenosine diphosphate (ADP)

48
Q

What does ADP induce by binding to its receptors?

A

Aggregation and recruitment of more platelets

49
Q

What is another mediator of platelet activation and aggregation?

A

Thromboxane

50
Q

What effect does thromboxane have on platelets?

A

They crosslink with each other

51
Q

What causes platelet activation to snowball?

A

Interlocking mechanisms

52
Q

What does thrombin stimulate in relation to platelets? What does thrombin induce the formation of?

A

Platelet activation
Fibrin

53
Q

What kind of process is platelet activation in clot formation? Why is platelet activation an obvious therapeutic target?

A

Self-reinforcing
It is crucial in blood clot formation

54
Q

What do activated platelets release to promote clot formation?

A

Prothrombotic molecules

55
Q

How does thrombin further stimulate platelet activation? What happens to the clot as platelet activation snowballs?

A

Through a continuous feedback loop
Clot grows rapidly